NorthWest Biotherapeutics Inc (NWBO)

[Barunuuk]

30% of P3(99 patients) have OS>25months

I actually think I may have to accumulate all of this and write an article. But here goes. I found some more good data when investigating GBM Rapid Progressors. The following study showed statistical significance in that cell cycle times may be used as predictor of survival. There were two groups they looked at, rapid progressors, which had tumor cell regrowth in less than 10 days, and then those > than 10 days. The found that in 42 GBM patients, the median OS for these two groups were 6.5 months and 9 months, meaning that after progression, the median patients lived 6.5 - 9 months longer.

Now looking at NWBO's historical literature to compare their 20 rapid progressors, they state comparable SOC values would be ~8.3 - 10.8 months. The rapid progressors were removed after month 2, so adding that to the literature value range above gives the 8.5 - 11 months. Nearly bang on.

Okay, so that said, if we know that ~83 patients had PFS events > or = to 16 months (as stated in numerous of my previous posts). Therefore, if there is a correlation of the length of time from tumor progression to overall survival, we know that the OS of these 83 will be > or = (and most likely greater) to 16+6.5 = 22.5 to 16 + 9 = 25 months. Assuming that since the patients have gone 16 months with no tumor progression, they are not rapid progressors, so they should at least be seeing OS of 25 months. Also that is assuming all 83 patients have tumor progression in Jan/Feb, which will not be the case.

Then again, incorporating historical SOC ratios to the other 248 (again conservative), of 30% living 24 months, that gives us ~50% of the 331 patients having an OS > then 24 months at minimum!

SO I guess what I am saying is, there is a lot of information pointing to an overall OS > 24 months.

https://www.ncbi.nlm.nih.gov/pubmed/18854836